Allylamine cardiovascular toxicity: Evidence for aberrant vasoreactivity in rats

Toxicology and Applied Pharmacology

Volumn 148, Issue 2, 1998, Pages 245-251

  Conklin, D J ^a   Boor, P J ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CORONARY ARTERY SPASM; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART RATE; NONHUMAN; RAT; SMOOTH MUSCLE CONTRACTILITY; SYSTOLIC BLOOD PRESSURE; TOXICITY TESTING; VASCULAR RING; VASCULAR SMOOTH MUSCLE; XENOBIOTIC METABOLISM;

ANIMALIA;

EID: 0032005785     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1997.8331     Document Type: Article

References (32)

1. Adolph E. F. Ranges of heart rates and their regulation at various ages (rat). Am. J. Physiol. 212:1967;595-602.
2. Awasthi S., Boor P. J. Semicarbazide protection from in vivo oxidant injury of vascular tissue by allylamine. Toxicol. Lett. 66:1993;157-163.
3. Benditt E. P., Benditt J. M. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc. Natl. Acad. Sci. USA. 70:1973;1753-1756.
4. Boor P. J., Nelson T. J. Allylamine cardiotoxicity: III. Protection by semicarbazide and in vivo derangements of monoamine oxidase. Toxicology. 18:1980;87-102.
5. Boor P. J., Ferrans V. J. Ultrastructural alterations in allylamine-induced cardiomyopathy: Early lesions. Lab. Invest. 47:1982;76-86.
6. Boor P. J., Ferrans V. J. Ultrastructural alterations in allylamine cardiovascular toxicity. Late myocardial and vascular lesions. Am. J. Pathol. 121:1985;39-54.
7. Boor P. J., Hysmith R. M. Allylamine cardiovascular toxicity: A review. Toxicology. 44:1987;129-144.
8. Boor P. J., Moslen M. T., Reynolds E. S. Allylamine cardiotoxicity. I. Sequence of pathologic events. Toxicol. Appl. Pharmacol. 50:1979;581-592.
9. Boor P. J., Hysmith R. M., Sanduja R. A role for a new vascular enzyme in the metabolism of xenobiotic amines. Circ. Res. 66:1990;249-252.
10. Burke T. M., Wolin M. S. Hydrogen peroxide elicits pulmonary arterial relaxation and guanylate cyclase activation. Am. J. Physiol. 252:1987;H721-H732.
11. Carlson E. L., Cant J. R., Sparks H. V. Coronary blood flow of unanaesthetized dogs with experimental coronary artery disease. Cardiovasc. Res. 7:1973;789-797.
12. Cox L. R., Ramos K. S. Biochemical basis of allylamine-induced aortic smooth muscle cell proliferation. Chemically Induced Cell Proliferation: Implications for Risk Assessment. 1991;Wiley-Liss, New York. p. 429-438.
13. Cox L. R., Murphy S. K., Ramos K. S. Modulation of phosphoinositide metabolism in aortic smooth muscle cells by allylamine. Exp. Mol. Pathol. 53:1990;52-63.
14. Elliot J., Callingham B. A. Effect of benzylamine and its metabolites on the response of the isolated perfused mesenteric arterial bed of the rat. J. Autom. Pharmacol. 11:1991;323-335.
15. Elliot J., Callingham B. A., Sharman D. F. Metabolism of amines in the isolated perfused mesenteric arterial bed of the rat. Br. J. Pharmacol. 98:1989;507-514.
16. Guzman R. J., Loquvam G. S., Kodama J. K., Hine C. H. Myocarditis produced by allylamines. Arch. Environ. Health. 2:1961;62-73.
17. Kato K., Nakazawa M., Masani F., Izumi T., Shibata A., Imai S. Ethanol ingestion on allylamine-induced experimental subendocardial fibrosis. Alcohol. 12:1995;233-239.
18. Lalich J. J., Allen J. R., Paik W. C. W. Myocardial fibrosis and smooth muscle cell hyperplasia in coronary arteries of allylamine-fed rats. Am. J. Pathol. 66:1972;225-240.
19. Lyles G. A., McDougal S. A. The enhanced daily excretion of urinary methylamine in rats treated with semicarbazide or hydralazine may be related to the inhibition of semicarbazide-sensitive amine oxidase activities. J. Pharm. Pharmacol. 41:1989;97-100.
20. Mellon R. R., Baker M. R., McIlroy A. P. Experimental necrotizing arteriolitis induced by a protein-cleavage product. Proc. Exp. Biol. Med. 33:1935;192-195.
21. Misra P., Srivastava S. K., Singhal S. S., Awasthi S., Awasthi Y. C., Boor P. J. GlutathioneS. Toxicol. Appl. Pharmacol. 133:1995;27-33.
22. Nicotera P., Bellomo G., Orrenius S. Calcium-mediated mechanisms in chemically induced cell death. Annu. Rev. Pharmacol. Toxicol. 32:1992;449-470.
23. Ramos K. S., Ou X. Protein kinase C (PKC)-mediated protein phosphorylation in rat aortic smooth muscle cells is enhanced by allylamine. Toxicol. Lett. 73:1994;123-133.
24. Ramos K. S., Grossman S. L., Cox L. R. Allylamine-induced vascular toxicity in vitro: Prevention by semicarbazide-sensitive amine oxidase inhibitors. Toxicol. Appl. Pharmacol. 95:1988;61-71.
25. Sanduja R., Ansari G. A. S., Boor P. J. Simultaneous determination of myocardial creatine phosphate and adenine nucleotides by reverse-phase high performance liquid chromatography. Biomed. Chromat. 2:1988;156-158.
26. Sklar J. L., Anderson P. G., Boor P. J. Allylamine and acrolein toxicity in perfused rat hearts. Toxicol. Appl. Pharmacol. 107:1991;535-544.
27. Toraason M., Luken M. E., Breitenstein M., Krueger J. A., Biagini R. E. Comparative toxicity of allylamine and acrolein in cultured myocytes and fibroblasts from neonatal rat heart. Toxicology. 56:1989;107-117.
28. Trent M. B., Boor P. J. Vascular amine oxidase activities during synergistic vasculotoxicity. Toxicology. 89:1994;67-77.
29. Waters L. L. Changes in the coronary arteries of dog following injections of allylamine. Am. Heart J. 35:1948;212-220.
30. Will, J. A. 1967, Allylamine induced cardiovascular changes in calves, University of Wisconsin.
31. Will J. A., Rowe G. C., Olson C., Crumpton C. W. A chemically induced acute model of myocardial damage in intact calves. Res. Comm. Chem. Path. Pharmacol. 2:1971;61-66.
32. Yu P. H., Zuo D. M. Formaldehyde produced endogenously via deamination of methylamine. A potential risk factor for initiation of endothelial injury. Atherosclerosis. 120:1996;189-197.